Table of Contents
Foreword ix
Edwin I. Goldenthal, PhD, ATS Preface xi
Contributors xiii
1 Introduction to the Study Director 1Mary Ellen Cosenza, PhD, MS, DABT, RAC
2 Good Laboratory Practice Regulations: Roles of the Study Director, Management, and Quality Assurance Unit 7Barbara Randolph, BS, MT (ASCP), MBA, RQAP (GLP)
3 International Guidelines and Regulations of Nonclinical Studies 27Bert Haenen, PhD, ERT, Linda Blous, Msc, and Anne Harman Chappelle, PhD, DABT
4 Facilities, Operations, Laboratory Animal Care, and Veterinary Services 43Susan A. MacKenzie, VMD, PhD, DABT, Gregory W. Ruppert, BA, and David G. Serota, PhD, DABT
5 Regulatory Inspections 73Russell James Eyre, PhD, DABT, Lijie Fu, PhD, MPH, Fellow ATS, and Eric Austin, PhD, DABT
6 Project Management and the Role of a Study Director 83Debra Kirchner, PhD, DABT, Parthena Martin, PhD, DABT, and Brenda Frantz, BS
7 Managing Multi-site Studies: Roles of the Principal Investigator and the Study Director 95Suzanne R.T. Wolford, PhD, DABT
8 Prestudy Preparation, the Protocol, Data Interpretation, and Reporting 107Carol S. Auletta, DABT, MBA, RAC
9 Study Conduct 131Lisa Biegel, PhD, Heather Dale, PhD, and Mark Morse, PhD, DABT
10 In Vitro Toxicology Models 145Gertrude-Emilia Costin, PhD, MBA, and Hans Raabe, MS
11 Analytical Chemistry and Toxicology Formulations 171Eric S. Bodle, PhD, and Nutan Gangrade, PhD
12 Statistical Design and Analysis of Studies 191John W. Green, PhD
13 Clinical Pathology 225Niraj K. Tripathi, BVSc, MVSc, PhD, DACVP, Lila Ramaiah, BSc, DVM, PhD, DACVP, and Nancy E. Everds, DVM, DACVP
14 Effective Incorporation and Utilization of Biomarkers in Nonclinical Studies 245Michael R. Bleavins, PhD, DABT
15 Pathology: Necropsy and Gross Pathology 259Charles B. Spainhour, VMD, PhD, DABT
16 Histopathology in Toxicity Studies for Study Directors 275Kevin Keane, DVM, PhD, Fellow IATP
17 Toxicokinetics and Bioanalysis 297Anthony L. Kiorpes, PhD, DVM, DABT
18 The Planning, Conduct, and Interpretation of Safety Pharmacology Studies: The Role of the Study Director in Safety Pharmacology Investigations 313Simon Authier, DVM, MSc, MBA, PhD, DSP, Michael J. Curtis, PhD, FHEA, FBPharmacolS, DSP, and Michael K. Pugsley, PhD, FBPharmacolS, DSP
19 Genetic Toxicology Studies 333Robert R. Young, MS, Mark Powley, PhD, Timothy E. Lawlor, MA, and Marilyn J. Aardema, PhD
20 Carcinogenicity Studies 355Reem Elbekai, BPharm, PhD, DABT, and Catherine M. Kelly, BS
21 Contemporary Practices in Core Developmental, Reproductive, and Juvenile Toxicity Assessments 371Ali Said Faqi, DVM, PhD, DABT, Fellow ATS
22 Immunotoxicology in Nonclinical Studies 393Florence G. Burleson, PhD, and Stefanie C.M. Burleson, PhD
23 Nonclinical Safety Assessment of Biotechnology-Derived Products: Considerations and Challenges 405Barbara Mounho, PhD, DABT
24 Gene and Cell Therapy Products 427Peter Working, PhD, DABT, Fellow ATS
25 Vaccines: Preventive and Therapeutic Product Studies 439Deborah L. Novicki, PhD, DABT, Jayanthi J. Wolf, PhD, Lisa M. Plitnick, PhD, and Melanie Hartsough, PhD
26 Toxicology Studies Conducted for Pesticides and Commodity Chemicals 465Elliot Gordon, PhD, DABT, and Linda A. Malley, PhD, DABT
27 Medical Devices 485Gregory A. Kopia, PhD, and John F. Dooley, PhD
28 Lessons from the Front Lines 505Christopher P. Chengelis, PhD, DABT, and C. Steven Godin, PhD, DABT
Index 519